Income statement
USD
Annual
| Metric | 2024 | 2017 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|
| Revenue | 0 | 5M | 4M | 7M | 4M |
| Gross Profit | 0 | 4M | 2M | 4M | 2M |
| Operating Income | -73M | 16K | 37K | 2M | 473K |
| EBITDA | -73M | 16K | 220K | 2M | 646K |
| Net Income | -73M | 16K | -461K | 438K | 522K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0155
+0.00% today
1Y Change
-37.87%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SETO Holdings, Inc. (SETO) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 37.9% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +99.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +99.5%, free cash flow 0.0% with operating margin -62.5% and ROIC -10.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.4. Stock Foundry combines SETO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SETO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SETO Max Drawdown
-79.52%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SETO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.6M
-51.1% YoY
FY Net Income
$521.7K
+19.2% YoY
Free Cash Flow
$10.2K
-98.9% YoY
Revenue Growth
+0.0%
EPS Growth
+99.5%
Gross Margin
34.0%
Net Margin
-62.5%
Income statement
USD
| Metric | 2024 | 2017 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|
| Revenue | 0 | 5M | 4M | 7M | 4M |
| Gross Profit | 0 | 4M | 2M | 4M | 2M |
| Operating Income | -73M | 16K | 37K | 2M | 473K |
| EBITDA | -73M | 16K | 220K | 2M | 646K |
| Net Income | -73M | 16K | -461K | 438K | 522K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2017 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 147K | 508K | 543K |
| Total Assets | 0 | 379K | 3M | 4M | 5M |
| Total Liabilities | 0 | 527K | 713K | 1M | 2M |
| Shareholder Equity | 0 | -147K | 2M | 3M | 3M |
| Total Debt | 0 | 367K | 442K | 607K | 1M |
| Net Debt | 0 | 367K | 295K | 99K | 633K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
212K
-84.5% YoY
Capital Expenditures
202K
+52.6% YoY
Free Cash Flow
10K
-98.9% YoY
Key ratios
Gross Margin
34.0%
Operating Margin
-62.5%
Net Margin
-62.5%
ROE
-15.4%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.